Market Alerts
-
Kymera Therapeutics Director Mark N Lampert Reported Purchase of 289,426 Shares @ Avg Price of $14.34/Share in Form 4 Filing on Tuesday
© 2022 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.... Read more
-
Kymera Therapeutics Received FDA Orphan Drug Designation for Treatment of Peripheral T-cell Lymphoma
https://www.accessdata.fda.gov/scripts/opdlisting/oopd/detailedIndex.cfm?cfgridkey=879422 © 2022 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.... Read more
-
Top WallStreetBets Mentions for Tuesday May 31, 2022 After-Hours: CRM, GME, TSLA, AMZN, HPQ, CHPT, APPS, VSCO, SNAP, NVDA
© 2022 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.... Read more
-
CORRECTION: BARK Sees Q1 2023 Revenue $130M Vs $138.5M Est; Sees FY23 Revenue $556M Vs $505.3M Est.
© 2022 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.... Read more
-
Boxed Files Prospectus Relates To Potential Offer, Sale From Time To Time By Jones Group Ventures LLC Of Up To 15M Shares Of Co's Common Stock
-SEC Filing © 2022 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.... Read more
-
FinVolution Reports Q1 2022 Transaction Volume RMB39.7B
© 2022 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.... Read more
-
CAE Q4 2022 Revenue C$955M Vs C$894.3M YoY; Adj. EPS C$0.29 Vs C$0.22 YoY
© 2022 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.... Read more
-
Salesforce Foreign Exchange Volatility Increased Revenue Headwind For Full-Year By $300M To Total Of $600M
-Reuters © 2022 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.... Read more
-
Forbes Will Scrap Plan To Go Public Via SPAC
-New York Times © 2022 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.... Read more
-
Bristow Group Q4 Sales $287.40M Miss $296.80M Estimate
V © 2022 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.... Read more
-
From Conf Call: Salesforce Said So Far Not Seeing Any Material Impact From Broader Economic World
© 2022 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.... Read more
-
TC Biopharm (Holdings) Files Amended Prospectus Related to Offering of 4.3M ADS's
© 2022 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.... Read more
-
Grom Social Enterprises Says On May 24, Co Received Notice Of Delisting Of Failure To Satisfy A Continued Listing Rule Or Standard From NASDAQ
-SEC Filing © 2022 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.... Read more
-
Laredo Petroleum Announces $200M Share Repurchase Program
Laredo Petroleum, Inc. (NYSE:LPI) ("Laredo" or the "Company") today announced that its board of directors authorized a $200 million share repurchase program. The two-year program is authorized through May 27, 2024. Highlights: $200 million share repurchase program realizes the Company's commitment to begin returning significant cash to shareholders approximately nine months ahead of schedule Debt repayment target updated to ~$700 million by year-end 2023 On track to achieve targeted Net Debt1/Consolidated EBITDAX1 ratio target of 1.0x by first-quarter 2023 Free Cash Flow1 for 2022-23 estimated at ~$900 million at current commodity prices © 2022 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.... Read more
-
Value Line Announces Renewal Of Stock Repurchase Program Of Up To $3M
Value Line, Inc., (NASDAQ: VALU) reported that on May 31, 2022, the Board of Directors approved a renewal of the share repurchase program, effective immediately, allowing the repurchase of shares from time to time, up to an additional amount of $3,000,000. The new repurchase program, which replaces the March 2022 program, has no set price limit and no expiration date and makes available a total of approximately $3.04 million. "Based on the Company's current financial picture, we believe that renewal of the repurchase program is in the best interests of our shareholders," said Howard A. Brecher, the Company's Chairman and Chief Executive Officer. © 2022 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.... Read more
